Future Plans for WVE-004 in C9-FTD and C9-ALS: Michael Panzara, MD, MPH скачать в хорошем качестве

Future Plans for WVE-004 in C9-FTD and C9-ALS: Michael Panzara, MD, MPH

“Should we see a change in the biomarker here, where the only explanation for that reduction is that we have done it with our drug and reduced an actual component of the pathophysiology of the disease, that would tell us that we are doing exactly what we set out to do, we are altering the natural course of this toxin, which will tell us that this is very likely to predict clinical effects in larger studies and longer studies.” Michael Panzara, MD, MPH, chief medical officer of Wave Life Sciences spoke on the FOCUS-C9 study and the potential of WVE-004 to generate positive outcomes for patients. For the original story, visit: (https://www.neurologylive.com/view/fu...)